



Newborn Screening for Pompe Disease

Guest Editors:

Prof. Dr. Wuh-Liang Hwu

Department of Pediatrics,
National Taiwan University
Hospital, Taipei 10041, Taiwan

Prof. Dr. Yin-Hsiu Chien

Department of Medical Genetics,
National Taiwan University
Hospital, Taipei 10041, Taiwan

Dr. Raymond Wang

Division of Metabolic Disorders,
Children's Hospital of Orange
County, Orange, CA 92868, USA

Deadline for manuscript
submissions:

closed (31 December 2019)

Message from the Guest Editors

Newborn screening is important for the early diagnosis and treatment of Pompe disease. The initial successes of Pompe disease newborn screening were from Taiwan, and currently, a good number of newborn screening programs have already started or are in the planning stages. However, screening for Pompe disease is not without its difficulties. There are a few assays available for screening. The accuracy of the assay as well as the screening algorithm determine the false positive and negative rates. Confirming diagnosis can be difficult, and genotype–phenotype correlation may not be established. Decision about when to initiate treatment, especially for late-onset Pompe disease, is difficult. To add to this, all these problems are further diverse among different ethnic groups. Through this Special Issue, experts in the field of newborn screening can share experiences in Pompe disease and help to accumulate data concerning prevalence, genotype, and phenotypes. More general readers of the Journal can also have the chance to understand Pompe disease and its screening. We think this Special Issue is just in time, and we thank all contributing authors in advance.





an Open Access Journal by MDPI

Editors-in-Chief

Dr. Peter C. J. I. Schielen

Office of the International Society
for Neonatal Screening,
Reigerskamp 273, 3607 HP
Maarsse, The Netherlands

Dr. Ralph Fingerhut

Newborn Screening and
Metabolic Laboratory, Synlab
MVZ Weiden, D-92637 Weiden,
Germany

Message from the Editorial Board

The *International Journal of Neonatal Screening (IJNS)* is owned by the International Society for Neonatal Screening. The journal is a publishing platform for all topics concerning newborn screening and covers clinical presentations, metabolite pattern detection, technical aspects, and “tips and tricks”. “Tips and tricks” will appear in the form of “Technical Notes” on the journal website, thus making *IJNS* the platform for NBS laboratories to share their valuable information as to how they have improved assays, workflow, and performance. Such improvements are sometimes achieved through tiny adaptations of existing methods, which normally remain in lab journals, but which might help improve the performance of NBS laboratories around the world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q1 (Pediatrics) / CiteScore - Q1 (Pediatrics, Perinatology and Child Health)

Contact Us

*International Journal of Neonatal
Screening* Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/IJNS
ijns@mdpi.com
X@IJNS_MDPI